Cellectar BiosciencesCLRB +1.20%28 FCF Yield % is -92.27 as of Jun. 27, 2026. GuruFocus rates CLRB with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,418 Biotechnology companies, Cellectar Biosciences ranks worse than 89.92% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Cellectar Biosciences FCF Yield % Related Terms
Cellectar Biosciences FCF Yield % Historical Data
* Premium members only.
The historical data trend for Cellectar Biosciences's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cellectar Biosciences's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellectar Biosciences FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cellectar Biosciences's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Cellectar Biosciences's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellectar Biosciences (CLRB) has a FCF Yield % of -92.27 as of Jun. 27, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Cellectar Biosciences and its competitors. According to the industry distribution chart, Cellectar Biosciences ranks #1275 out of 1418 companies in the Biotechnology industry, placing it in the top 89.9%.
Is Cellectar Biosciences' FCF Yield % too high?
Cellectar Biosciences' current FCF Yield % is -92.27. Based on the distribution chart, Cellectar Biosciences ranks #1275 out of 1418 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cellectar Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Cellectar Biosciences' FCF Yield % compare to PTN and PLUR?
According to the Biotechnology industry distribution chart, Cellectar Biosciences ranks #1275 out of 1418 companies for FCF Yield %. This places Cellectar Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Cellectar Biosciences and its competitors. Cellectar Biosciences's current FCF Yield % is -92.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellectar Biosciences stock overvalued right now?
Cellectar Biosciences (CLRB) has a current FCF Yield % of -92.27. The current FCF Yield % is -92.27. Cellectar Biosciences' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Cellectar Biosciences (CLRB), the current FCF Yield % is -92.27 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
28GF Score
Get the complete analysis for CLRB
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLRB has been successfully added to your 
